Payment overview · 2025
General Payments
$711.90
36 reported records · 10 companies
Healthcare provider profile · identity verified
Eddy Simon, MD
Allopathic & Osteopathic Physicians|Internal Medicine · EAST ORANGE, NJ · NPI 1851385058
Verified facts
What the public records show
CMS Open Payments records show Eddy Simon, MD received $711.90 in general payments during 2025 across 36 reported records.
Novo Nordisk Inc accounted for 41.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $294.91 | 41.4% | 12 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $85.56 | 12.0% | 5 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $72.65 | 10.2% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $65.11 | 9.2% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $50.49 | 7.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.95 | 6.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.02 | 5.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27.96 | 3.9% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $16.93 | 2.4% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.32 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $711.90 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $248.65 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $104.28 | 6 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $72.65 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $50.49 | 3 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $50.06 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.03 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.51 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $27.96 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.03 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 54 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 63 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 503 | 182 |
| Atorvastatin Calcium | Atorvastatin Calcium | 477 | 178 |
| Metformin Hcl | Metformin Hcl | 273 | 98 |
| Losartan Potassium | Losartan Potassium | 267 | 94 |
| Omeprazole | Omeprazole | 194 | 79 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 57 |
| Ibuprofen | Ibuprofen | 160 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 160 | 55 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 130 | 63 |
| Montelukast Sodium | Montelukast Sodium | 129 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 31 |
| Simvastatin | Simvastatin | 96 | 33 |
| Tramadol Hcl | Tramadol Hcl | 96 | 26 |
| Trazodone Hcl | Trazodone Hcl | 96 | 40 |
| Lisinopril | Lisinopril | 94 | 35 |
| Gabapentin | Gabapentin | 89 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 32 |
| Januvia | Sitagliptin Phosphate | 71 | 20 |
| Azithromycin | Azithromycin | 68 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 65 | 25 |
| Linzess | Linaclotide | 63 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 61 | 31 |
| Carvedilol | Carvedilol | 57 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 21 |
| Glimepiride | Glimepiride | 57 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 23 |
| Jardiance | Empagliflozin | 54 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 16 |
| Eliquis | Apixaban | 49 | 17 |
| Ezetimibe | Ezetimibe | 47 | 14 |
| Rybelsus | Semaglutide | 44 | 13 |
| Alendronate Sodium | Alendronate Sodium | 42 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 11 |
| Meclizine Hcl | Meclizine Hcl | 41 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 38 | 20 |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Chlorthalidone | Chlorthalidone | 36 | 13 |
| Famotidine | Famotidine | 36 | 12 |
| Potassium Chloride | Potassium Chloride | 36 | suppressed |
| Tradjenta | Linagliptin | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Furosemide | Furosemide | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 24 |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 25 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | 11 |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Repaglinide | Repaglinide | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $711.90 · 36 records | Novo Nordisk Inc | Cologuard Collection Kit, JARDIANCE, LINZESS, LUMRYZ, MOUNJARO, NUCALA, Ohtuvayre, Ozempic, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UPTRAVI, Wegovy, YUPELRI | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error